Alipogene tiparvovec

N/A

Report date: 2025/02/10 20:00:43

Base Information

Drug NameAlipogene tiparvovec
Drug Alias Namealipogenum tiparvovecum替帕阿立泊集LPL gene therapy - AMT阿利泼金替-阿利珀近 +[12] 
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector > AAV1 vector
Mechanisms of ActionLipoprotein lipase stimulantsGene transference
TargetsLipoprotein lipase
Therapy Area/IndicationsHyperlipoproteinemia Type I
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesUniqure Biopharma Bv
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAmsterdam Molecular TherapeuticsUniqure Biopharma BvChiesi Farmaceutici SPA
Active IndicationsN/A
Inactive IndicationsHyperlipoproteinemia Type I

Other Information

ATC CodeC10AX10
Related LinksWikipediaKEGG